Cohance Lifesciences Limited
1,083words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
42.73%
1FY21 H1FY22 H1FY21 H1FY22 Note:Figures in Rs. Crore 6 Financial Snapshot Growth in Revenue 42.73% Growth in EBITDA Growth in PAT 62.99% 76.33% 26.40% 30.11% 34.17% Q2FY22 H1FY22 7 Key Ra
62.99%
es in Rs. Crore 6 Financial Snapshot Growth in Revenue 42.73% Growth in EBITDA Growth in PAT 62.99% 76.33% 26.40% 30.11% 34.17% Q2FY22 H1FY22 7 Key Ratios Growth in EBIT 44.48% EBITDA to
76.33%
. Crore 6 Financial Snapshot Growth in Revenue 42.73% Growth in EBITDA Growth in PAT 62.99% 76.33% 26.40% 30.11% 34.17% Q2FY22 H1FY22 7 Key Ratios Growth in EBIT 44.48% EBITDA to Income
26.40%
6 Financial Snapshot Growth in Revenue 42.73% Growth in EBITDA Growth in PAT 62.99% 76.33% 26.40% 30.11% 34.17% Q2FY22 H1FY22 7 Key Ratios Growth in EBIT 44.48% EBITDA to Income PAT to
30.11%
ncial Snapshot Growth in Revenue 42.73% Growth in EBITDA Growth in PAT 62.99% 76.33% 26.40% 30.11% 34.17% Q2FY22 H1FY22 7 Key Ratios Growth in EBIT 44.48% EBITDA to Income PAT to Income
34.17%
apshot Growth in Revenue 42.73% Growth in EBITDA Growth in PAT 62.99% 76.33% 26.40% 30.11% 34.17% Q2FY22 H1FY22 7 Key Ratios Growth in EBIT 44.48% EBITDA to Income PAT to Income 47.19%
44.48%
owth in PAT 62.99% 76.33% 26.40% 30.11% 34.17% Q2FY22 H1FY22 7 Key Ratios Growth in EBIT 44.48% EBITDA to Income PAT to Income 47.19% 33.95% 43.08% 46.07% 32.29% Q2FY22 H1FY22 8 Fina
47.19%
34.17% Q2FY22 H1FY22 7 Key Ratios Growth in EBIT 44.48% EBITDA to Income PAT to Income 47.19% 33.95% 43.08% 46.07% 32.29% Q2FY22 H1FY22 8 Financials Q2FY22 Revenue EBIDTA PAT 3,393
33.95%
Q2FY22 H1FY22 7 Key Ratios Growth in EBIT 44.48% EBITDA to Income PAT to Income 47.19% 33.95% 43.08% 46.07% 32.29% Q2FY22 H1FY22 8 Financials Q2FY22 Revenue EBIDTA PAT 3,393 2,696
43.08%
H1FY22 7 Key Ratios Growth in EBIT 44.48% EBITDA to Income PAT to Income 47.19% 33.95% 43.08% 46.07% 32.29% Q2FY22 H1FY22 8 Financials Q2FY22 Revenue EBIDTA PAT 3,393 2,696 2,377 N
46.07%
7 Key Ratios Growth in EBIT 44.48% EBITDA to Income PAT to Income 47.19% 33.95% 43.08% 46.07% 32.29% Q2FY22 H1FY22 8 Financials Q2FY22 Revenue EBIDTA PAT 3,393 2,696 2,377 N M S E E
32.29%
Ratios Growth in EBIT 44.48% EBITDA to Income PAT to Income 47.19% 33.95% 43.08% 46.07% 32.29% Q2FY22 H1FY22 8 Financials Q2FY22 Revenue EBIDTA PAT 3,393 2,696 2,377 N M S E E P U R
Advertisement